Loss of fibulin-2 protects against progressive ventricular dysfunction after myocardial infarction
Takeshi Tsuda(DuPont (United States)), Mon‐Li Chu(Thomas Jefferson University), Thomas L. Miller(G1 Therapeutics (United States)), Jing Wu(Alfred I. duPont Hospital for Children), Xingliang Ma(Thomas Jefferson University), Yaqun Zou(National Institutes of Health), Erhe Gao(Temple University), Hangxiang Zhang(Alfred I. duPont Hospital for Children), Feng Gao(Northwestern Polytechnical University), Walter J. Koch(Duke University), Ying Liu(Shanghai First Maternity and Infant Hospital), Jennifer Joyce(Alfred I. duPont Hospital for Children), Dessislava Markova(Thomas Jefferson University Hospital), Hailong Dong(Chinese Academy of Tropical Agricultural Sciences)
Cited by 37
Related Papers
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
|The Lancet|2020|29.1k
Adrenergic Nervous System in Heart Failure
|Circulation Research|2013|597
A novel protective effect of erythropoietin in the infarcted heart
|Journal of Clinical Investigation|2003|549
Caution on Kidney Dysfunctions of COVID-19 Patients
|medRxiv|2020|431
Neuronal network activity controls microglial process surveillance in awake mice via norepinephrine signaling
|Nature Neuroscience|2019|424